Get informed when a big investor buys or sells
+ FollowOvervalued by 109.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $141.70 Million |
|---|---|
| Enterprise Value | $146.07 Million |
| Earnings per Share | $-0.55 |
| Beta | 0.86 |
| Outstanding Shares | 93,826,793 |
| P/E Ratio | -2.35 |
|---|---|
| PEG | 34.47 |
| Price to Sales | - |
| Price to Book Ratio | -1.51 |
| Enterprise Value to Revenue | 15.54 |
| Enterprise Value to EBIT | -1.44 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -0.27 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company...